与囊性纤维化无关的支气管感染患者吸入抗生素的短期耐受性

Q4 Medicine
Luis Máiz , Rosa Nieto , Diego Durán , José Máiz , Gabriel Ruiz-Calvo , Alfonso Muriel , Esther Barbero , Manuel Vélez-Díaz-Pallarés , Raquel Morillo
{"title":"与囊性纤维化无关的支气管感染患者吸入抗生素的短期耐受性","authors":"Luis Máiz ,&nbsp;Rosa Nieto ,&nbsp;Diego Durán ,&nbsp;José Máiz ,&nbsp;Gabriel Ruiz-Calvo ,&nbsp;Alfonso Muriel ,&nbsp;Esther Barbero ,&nbsp;Manuel Vélez-Díaz-Pallarés ,&nbsp;Raquel Morillo","doi":"10.1016/j.opresp.2025.100460","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>The use of intravenous antibiotic formulations delivered by inhalation is controversial. Tolerance can be an issue and some treatment guidelines discourage this route of administration if the same antibiotic is available in an inhalation formulation.</div></div><div><h3>Material and methods</h3><div>This was a retrospective, observational, single-center study comparing tolerance to three antibiotics delivered by nebulization (intravenous formulations of ampicillin and gentamicin, and an inhalation formulation of colistimethate sodium) in patients with bronchial infection (BI), chronic bronchial infection (CBI), and/or recurrent respiratory infections. The study also aimed to identify factors potentially associated with tolerability.</div></div><div><h3>Results</h3><div>A total of 330 antibiotic tolerance tests were performed in 135 patients (mean age 68 years; 48.9% female; mean post-bronchodilator FEV<sub>1</sub>% predicted 65.9%). Of these patients, 62.2% had bronchiectasis and 39.3% had chronic obstructive pulmonary disease (COPD). The best tolerated antibiotic was colistimethate. Overall, 89.6% of colistimethate doses were tolerated, compared to 69.5% of inhaled gentamicin doses (<em>P</em> <!-->&lt;<!--> <!-->0.001) and 69.1% of ampicillin doses (<em>P</em> <!-->&lt;<!--> <!-->0.001). Compared with colistimethate administration, the odds of intolerance were 5.69 times higher for gentamicin (<em>P</em> <!-->&lt;<!--> <!-->0.001) and 6.21 times higher for ampicillin (<em>P</em> <!-->&lt;<!--> <!-->0.001). In the univariate analysis, factors that may have been associated with antibiotic intolerance included smoking habit, worse post-bronchodilator FEV<sub>1</sub>% predicted and a diagnosis of COPD. In the multivariate analysis, after adjustment for antibiotic type, smoking habit, post-bronchodilator FEV<sub>1</sub> and COPD diagnosis, the only factor influencing tolerance was the type of antibiotic used.</div></div><div><h3>Conclusion</h3><div>In patients with BI and/or CBI and/or recurrent respiratory infections, inhaled sodium colistimethate is significantly better tolerated than intravenous formulations of gentamicin and ampicillin for the inhalation route. The only factor influencing tolerance is the type of antibiotic used.</div></div>","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"7 3","pages":"Article 100460"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Short-term Tolerance to Inhaled Antibiotics in Patients With Bronchial Infection not Associated With Cystic Fibrosis\",\"authors\":\"Luis Máiz ,&nbsp;Rosa Nieto ,&nbsp;Diego Durán ,&nbsp;José Máiz ,&nbsp;Gabriel Ruiz-Calvo ,&nbsp;Alfonso Muriel ,&nbsp;Esther Barbero ,&nbsp;Manuel Vélez-Díaz-Pallarés ,&nbsp;Raquel Morillo\",\"doi\":\"10.1016/j.opresp.2025.100460\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>The use of intravenous antibiotic formulations delivered by inhalation is controversial. Tolerance can be an issue and some treatment guidelines discourage this route of administration if the same antibiotic is available in an inhalation formulation.</div></div><div><h3>Material and methods</h3><div>This was a retrospective, observational, single-center study comparing tolerance to three antibiotics delivered by nebulization (intravenous formulations of ampicillin and gentamicin, and an inhalation formulation of colistimethate sodium) in patients with bronchial infection (BI), chronic bronchial infection (CBI), and/or recurrent respiratory infections. The study also aimed to identify factors potentially associated with tolerability.</div></div><div><h3>Results</h3><div>A total of 330 antibiotic tolerance tests were performed in 135 patients (mean age 68 years; 48.9% female; mean post-bronchodilator FEV<sub>1</sub>% predicted 65.9%). Of these patients, 62.2% had bronchiectasis and 39.3% had chronic obstructive pulmonary disease (COPD). The best tolerated antibiotic was colistimethate. Overall, 89.6% of colistimethate doses were tolerated, compared to 69.5% of inhaled gentamicin doses (<em>P</em> <!-->&lt;<!--> <!-->0.001) and 69.1% of ampicillin doses (<em>P</em> <!-->&lt;<!--> <!-->0.001). Compared with colistimethate administration, the odds of intolerance were 5.69 times higher for gentamicin (<em>P</em> <!-->&lt;<!--> <!-->0.001) and 6.21 times higher for ampicillin (<em>P</em> <!-->&lt;<!--> <!-->0.001). In the univariate analysis, factors that may have been associated with antibiotic intolerance included smoking habit, worse post-bronchodilator FEV<sub>1</sub>% predicted and a diagnosis of COPD. In the multivariate analysis, after adjustment for antibiotic type, smoking habit, post-bronchodilator FEV<sub>1</sub> and COPD diagnosis, the only factor influencing tolerance was the type of antibiotic used.</div></div><div><h3>Conclusion</h3><div>In patients with BI and/or CBI and/or recurrent respiratory infections, inhaled sodium colistimethate is significantly better tolerated than intravenous formulations of gentamicin and ampicillin for the inhalation route. The only factor influencing tolerance is the type of antibiotic used.</div></div>\",\"PeriodicalId\":34317,\"journal\":{\"name\":\"Open Respiratory Archives\",\"volume\":\"7 3\",\"pages\":\"Article 100460\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Respiratory Archives\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2659663625000645\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Respiratory Archives","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2659663625000645","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

静脉吸入抗生素制剂的使用是有争议的。耐受性可能是一个问题,如果吸入制剂中有相同的抗生素,一些治疗指南不鼓励这种给药途径。材料和方法这是一项回顾性、观察性、单中心研究,比较支气管感染(BI)、慢性支气管感染(CBI)和/或复发性呼吸道感染患者对三种抗生素(氨苄西林和庆大霉素静脉制剂,以及粘菌酸钠吸入性制剂)雾化递送的耐受性。该研究还旨在确定与耐受性相关的潜在因素。结果135例患者共进行330次抗生素耐受性试验,平均年龄68岁;48.9%的女性;平均支气管扩张剂后FEV1%预测65.9%)。在这些患者中,62.2%患有支气管扩张,39.3%患有慢性阻塞性肺疾病(COPD)。耐受性最好的抗生素是大肠杆菌酸酯。总体而言,89.6%的粘菌素耐受性,而吸入庆大霉素耐受性为69.5% (P <;0.001)和69.1%的氨苄西林剂量(P <;0.001)。庆大霉素不耐受的几率是大肠杆菌耐酸组的5.69倍(P <;0.001),氨苄西林高6.21倍(P <;0.001)。在单变量分析中,可能与抗生素不耐受相关的因素包括吸烟习惯、使用支气管扩张剂后fev1(预测为1%)恶化和COPD诊断。在多因素分析中,在调整抗生素类型、吸烟习惯、支气管扩张剂后FEV1和COPD诊断后,影响耐受性的唯一因素是使用的抗生素类型。结论在BI和/或CBI和/或复发性呼吸道感染患者中,吸入型粘菌素钠的耐受性明显优于静脉注射庆大霉素和氨苄西林制剂。影响耐药性的唯一因素是所使用的抗生素类型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Short-term Tolerance to Inhaled Antibiotics in Patients With Bronchial Infection not Associated With Cystic Fibrosis

Introduction

The use of intravenous antibiotic formulations delivered by inhalation is controversial. Tolerance can be an issue and some treatment guidelines discourage this route of administration if the same antibiotic is available in an inhalation formulation.

Material and methods

This was a retrospective, observational, single-center study comparing tolerance to three antibiotics delivered by nebulization (intravenous formulations of ampicillin and gentamicin, and an inhalation formulation of colistimethate sodium) in patients with bronchial infection (BI), chronic bronchial infection (CBI), and/or recurrent respiratory infections. The study also aimed to identify factors potentially associated with tolerability.

Results

A total of 330 antibiotic tolerance tests were performed in 135 patients (mean age 68 years; 48.9% female; mean post-bronchodilator FEV1% predicted 65.9%). Of these patients, 62.2% had bronchiectasis and 39.3% had chronic obstructive pulmonary disease (COPD). The best tolerated antibiotic was colistimethate. Overall, 89.6% of colistimethate doses were tolerated, compared to 69.5% of inhaled gentamicin doses (P < 0.001) and 69.1% of ampicillin doses (P < 0.001). Compared with colistimethate administration, the odds of intolerance were 5.69 times higher for gentamicin (P < 0.001) and 6.21 times higher for ampicillin (P < 0.001). In the univariate analysis, factors that may have been associated with antibiotic intolerance included smoking habit, worse post-bronchodilator FEV1% predicted and a diagnosis of COPD. In the multivariate analysis, after adjustment for antibiotic type, smoking habit, post-bronchodilator FEV1 and COPD diagnosis, the only factor influencing tolerance was the type of antibiotic used.

Conclusion

In patients with BI and/or CBI and/or recurrent respiratory infections, inhaled sodium colistimethate is significantly better tolerated than intravenous formulations of gentamicin and ampicillin for the inhalation route. The only factor influencing tolerance is the type of antibiotic used.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Open Respiratory Archives
Open Respiratory Archives Medicine-Pulmonary and Respiratory Medicine
CiteScore
1.10
自引率
0.00%
发文量
58
审稿时长
51 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信